Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2018 16:01 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
October 02, 2018 08:30 ET | Source: Dermira, Inc.

Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin

Mr. Siriano invites the millions of people living with hyperhidrosis in the U.S. to share their ‘sweat stories’ MENLO PARK, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a...
October 01, 2018 07:30 ET | Source: Dermira, Inc.

Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis

QBREXZA is now available in retail and community pharmacies across the United StatesQBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years...
September 25, 2018 08:00 ET | Source: Dermira, Inc.

Dermira to Present at Cantor 2018 Global Healthcare Conference

MENLO PARK, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
September 13, 2018 06:00 ET | Source: Dermira, Inc.

Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress

Primary axillary hyperhidrosis is a medical condition that can occur in the pediatric population and is largely undertreated and under-diagnosedPost-hoc analysis of ARIDO long-term safety study...
September 10, 2018 16:02 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
September 05, 2018 07:30 ET | Source: Dermira, Inc.

Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis

Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRxCompany announces DermiraConnect, a new patient access program that will provide patients broad access to...
August 08, 2018 20:14 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
August 06, 2018 16:01 ET | Source: Dermira, Inc.

Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update

- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018- QBREXZA expected to be available nationwide in pharmacies beginning in October 2018-...
July 10, 2018 16:01 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right